Dyskeratosis Congenita and Short Telomeres in a Female Patient

Keywords: Dyskeratosis Congenita, Telomere


Dyskeratosis Congenita (DC) is a hereditary and multisystemic syndrome, with heterogeneous clinical and genetic manifestations, characterized as a disease associated with maintenance of defects and early telomere shortening. It is a rare condition, with an estimated annual incidence of 1 in 1 million individuals, and is more common in males than females, with an approximate ratio of 10:1. The main initial clinical manifestations are disorders of cutaneous pigmentation, nail dystrophy and abnormalities in the oropharynx, usually occurring between five and twelve years of age. Bone marrow failure (BMF) is the leading cause of death related to this disease. We present a case report of a child, female, two years old, who presented the cardinal signs and symptoms of DC at an early age, and we emphasize the importance of multidisciplinary monitoring of the patient.


Download data is not yet available.


Shimamura A, Alter BP. Pathophysiology and management of inherited bone marrow failure syndromes. Blood Rev. 2010;24:101-22. doi: 10.1016/j.blre.2010.03.002.

Noto Z, Tomihara K, Furukawa K, Noguchi M. Dyskeratosis congenita associated with leukoplakia of the tongue. Int J Oral Maxillofac Surg. 2016;45:760-3. doi: 10.1016/j.ijom.2015.12.005.

Fernández García MS, Teruya-Feldstein J. The diagnosis and treatment of dyskeratosis congenita: A review. J Blood Med. 2014;5:157-67. doi: 10.2147/JBM.S47437.

Kumar S, Suthar R. Dyskeratosis congenita. JK Sci. 2013;15:56-8.

Savage SA, Cook EF. Dyskeratosis Congenita and Telomere Biology Disorders: Diagnosis and Management Guidelines. New York: Dyskeratosis Congenita Outreach, Inc; 2015.[accessed Jan 2020] Available from: https://teamtelomere.org/wp-content/uploads/2018/07/DC-TBD-Diagnosis-And-Management-Guidelines.pdf

U.S. National Library of Medicine, Genetics Home Reference. Dyskeratosis Congenita 2014. [accessed Jan 2020] Available from:https://ghr.nlm.nih.gov/condition/dyskeratosis-congenita#statistics.

Knight S, Vulliamy T, Copplestone A, Gluckman E, Mason P, Dokal I. Dyskeratosis congenita (DC) registry: Identification of new features of DC. Br J Haematol. 1998;103:990-6. doi: 10.1046/j.1365-2141.1998.01103.x.

Handley TPB, McCaul JA, Ogden GR. Dyskeratosis congenita. Oral Oncol. 2006;42:331-6. doi: 10.1016/j.oraloncology.2005.06.007.

Güngör Ş, Erdemir AV, Göncü EK, Gürel MS, Özekinci S. A case of dyskeratosis congenita with dermoscopic and reflectance confocal microscopic features. J Am Acad Dermatol. 2015;73:e11-3. doi: 10.1016/j.jaad.2015.02.1141.

Walne AJ, Dokal I. Advances Dyskeratosis Congenita. Br J Haematol. 2010;145:164-72. doi: 10.1111/j.1365-


Khincha PP, Wentzensen IM, Giri N, Alter BP, Savage SA. Response to androgen therapy in patients with dyskeratosis congenita. Br J Haematol. 2014;165:349-57. doi: 10.1111/bjh.12748.

How to Cite
Vinha Zanuncio, V., & Oliveira Rocha, K. (2020). Dyskeratosis Congenita and Short Telomeres in a Female Patient. Journal of the Portuguese Society of Dermatology and Venereology, 78(4), 369-372. https://doi.org/10.29021/spdv.78.4.1230
Case Reports